Skip to main content
Explore URMC

URMC Logo

menu

Open Studies

Our studies are sponsored by the National Cancer Institute (NCI) and affiliated national cooperative research groups, industry, and individual principal investigators (PI).

Study Locations

  • SMH: Strong Memorial Hospital
  • HH: Highland Hospital
  • PR: Cancer Center at Park Ridge
  • Sands: Sands Cancer Center

 

SITE SPONSOR LOCAL # LOCATION(S) OPEN STUDY TITLE
Any NRG ARST1321 SMH Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
Bone Marrow PI 3705 SMH Genotoxicity Assessment for Patients Receiving Ionizing Radiation for Treatment or Receiving Diagnostic Imaging Scans
  PI 47391 SMH A Tissue Procurement Protocol to Investigate Molecular and Genetic Markers/Predictors of Cardiac Toxicity from Cancer Treatment
Brain RTOG 834 SMH, HH (EORTC 26053-22054) Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial
  RTOG 1114 SMH Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
  RTOG 1205 SMH, HH Randomized Phase II Trial of Concurrent Bevacizumab and Re-irradiation vs. Bevacizumab Alone as Treatment for Recurrent Glioblastoma
  RTOG 1470 SMH (AO71101): A Phase II Randomized Trial Coparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC#725085, Alliance IND #15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma
  Alliance A221101 SMH, HH, PR A Phase III Randomized Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) to Reduce Cancer-Related Fatigue in Patients with High Grade Glioma
Gastrointestinal RTOG 848 SMH, HH A Phase III Trial of Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
  RTOG 1010 SMH, HH A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
  RTOG 1112 SMH Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
  RTOG 1201 SMH A Phase III Randomized Trial Evaluating the Addition of High or Standard Intensity Radiation to Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Cancer
  PI ULAB11068 SMH Analysis of Clinical Data and Lung Dose Using Volumetric Analysis in Patients Treated with Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma
  PI UGUP14107 SMH, HH Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer
Genitourinary RTOG 815 SMH, HH, PR, Sands A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients with Intermediate Risk Prostate Cancer
  RTOG 0926 SMH A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following A Thorough Transurethral Surgical Re-Staging
  PI UCCS14115 SMH, HH CDC SIP: Rochester Prevention Research Center: Development and Evaluation of an Active Surveillance Decision Aid for Men with Low Grade Prostate Cancer
Gynecologic RTOG 724 SMH, HH Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Head and Neck Industry CTIX-BRI-205 SMH, HH, Sands Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brilacidin Oral Rinse Administered Daily for 7 Weeks in Attenuating Oral Mucositis in Patients with Head and Neck Cancer Receiving Concurrent Chemotherapy and Radiotherapy
  Industry GT001 SMH A Phase I, Open-Label, Multi-Center, Dose Escalation Study of the Safety, Tolerability, Pharmacodynamic, and Pharmacokinetic Properties of Intravenous GC4419 in Combination with Radiation and Chemotherapy for Squamous Cell Cancers of the Head and Neck
  RTOG 920 SMH, HH, PR, Sands A Phase III Study of Postop RT (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
  RTOG 1216 SMH, HH, PR, Sands Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
Lung RTOG 538 SMH, HH, PR, Sands (CALGB 30610) Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Stage Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
  RTOG 1306 SMH A Randomized Phase III Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
  PI 46718 SMH Abraxane: A Randomized Phase I/II Study of Nab-Paclitaxel, or Paclitaxel, Plus Carboplatin with Concurrent Radiation Therapy Followed by Consolidation in Patients with Favorable Prognosis Inoperable Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Metastases from Breast NRG BR002 SMH A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Metastases to Brain RTOG 1119 SMH Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastases from HER2-positive Breast Cancer
Metastases to Multiple Organs NRG BR001 SMH A Phase I Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases